FTSE Today Live Incanthera’s Skin+CELL Skincare Expansion

Highlights

• Incanthera plc (LSE:INC) reported its final audited results for the year ended March

• The company launched its Skin+CELL luxury skincare range via a Direct To Consumer platform

• Expansion builds on dermatology and oncology expertise supported by proprietary delivery systems

Incanthera plc expands its dermatology focus with the launch of Skin+CELL skincare, merging oncology expertise and luxury cosmetics across UK markets.

Incanthera plc (LSE:INC) operates in the healthcare and cosmetics field, with its primary focus on dermatology and oncology. Established out of the Institute of Cancer Therapeutics at the University of Bradford, the company is known for its innovative delivery technologies that apply to both therapeutic and cosmetic use. The group’s final results for the year ended March highlight progress in dermatology, with the commercial launch of Skin+CELL, a luxury skincare line designed to combine scientific precision with premium cosmetic application. Operating alongside businesses across the broader ftse today live, Incanthera demonstrates how science-led healthcare enterprises continue to expand within UK markets. Though not a constituent of larger indices such as the ftse 100 or ftse 250, the company’s progress reflects the diversity of healthcare-driven enterprises found across the equity landscape.

What Does the Skin+CELL Range Represent in Dermatology?

The Skin+CELL range is positioned as a scientifically informed luxury skincare brand. The formulations centre on Bioactive B3, also known as niacinamide, delivered through patented pathways designed by Incanthera’s in-house experts. Independent studies have confirmed that the formulation technology demonstrates protective effects against UV-induced cellular damage, which places the brand in a unique space where pharmaceutical design meets consumer cosmetics. The current product line extends across face care, body care, hand care, facial serums, and eye creams, with further developments expected to include sun protection factors and other bioactive vitamin derivatives.

How Did the Direct To Consumer Launch Progress?

The global launch of Skin+CELL took place in August with the introduction of a dedicated e-commerce platform. The business model relies on Direct To Consumer strategy, enabling direct engagement with audiences across global markets. Orders are fulfilled via third-party logistics support based in Switzerland, ensuring that products reach consumers with consistent quality and delivery standards. Marketing efforts have been extensive across major social media channels, including Instagram, TikTok, Facebook, and YouTube. The campaigns were designed to highlight both the scientific aspects of the formulations and the luxury positioning of the brand, with tailored content produced for each platform. This approach provided visibility to different demographics while ensuring brand consistency.

What Role Does Oncology Expertise Play in Cosmetic Innovation?

Incanthera’s foundation in oncology research significantly informs its cosmetic development. Oncology studies often focus on cellular responses, resilience, and repair mechanisms. Applying this expertise to dermatology has resulted in skincare formulations that energise living cells of the skin, strengthening protective functions and maintaining even skin tone. This cross-disciplinary application of science into consumer products illustrates the connection between clinical research and the luxury cosmetics sector. By applying oncology-derived knowledge, the company has been able to create skincare that is positioned as clinically designed yet commercially viable.

How Is the Company Supporting the Skincare Rollout?

The rollout of Skin+CELL is supported through a robust manufacturing and logistics framework. Production is managed by Frike, a Swiss-based company that also supplies to other leading skincare firms globally. Distribution is coordinated through a logistics facility that handles order fulfilment, packaging, and consumer delivery. The Direct To Consumer model offers flexibility in scaling operations and provides a consistent user experience, supported by digital-first engagement strategies. The company has indicated plans for expanding the range into formulations with SPF concentrations and further bioactive derivatives, enhancing its presence in dermatology-based cosmetics.

How Do UK Indices Reflect the Healthcare Segment?

Healthcare and cosmetics-focused businesses feature across multiple UK indices such as the ftse 350 and FTSE AIM 100 Index. These platforms illustrate the growing role of scientific innovation within the consumer healthcare space. While Incanthera plc is listed on AQSE, its work aligns with trends visible across these indices, where companies merge pharmaceutical expertise with consumer-facing product portfolios. The healthcare segment across UK markets remains diverse, ranging from biotechnology enterprises to cosmetics manufacturers, each showcasing the importance of research-driven outcomes.

How Is Media Exposure Supporting Brand Awareness?

The brand’s promotional activities include collaborations with influencers and targeted campaigns across social media. Content strategies have included bespoke video production, short advertisements, and influencer-led endorsements, designed to emphasise both the science and luxury positioning of the range. Traditional beauty media outlets have also provided coverage, placing the product within mainstream cosmetic discussions while reinforcing its dermatological background. This layered approach to promotion ensures visibility across lifestyle audiences and specialist consumer segments.

What Defines the Business Model for Expansion?

The Direct To Consumer model is central to Incanthera’s commercialisation plan. By relying on this structure, the company maintains direct oversight of consumer engagement, digital content, and brand messaging. It also allows the group to respond quickly to consumer feedback and adjust product lines or campaigns accordingly. Additional promotional activities are anticipated for seasonal periods, broadening awareness in retail, beauty, and science-related media. Alongside this model, the company has also expressed interest in exploring retail and wholesale pathways, highlighting a multi-channel approach to expansion.

What Innovations Support Skin+CELL Technology?

The Skin+CELL formulations are supported by advanced delivery technologies that optimise the transport of active ingredients directly into skin cells. These pathways were designed to ensure targeted absorption, enhancing the bioavailability of ingredients like Bioactive B3. The formulations combine pharmaceutical enhancement methods with cosmetic components, producing products that are clinically effective while maintaining luxury qualities such as silky texture and visible radiance after use. In addition to current offerings, development continues in areas such as sun care and environmental protection products.

What Are the Broader Implications for Dermatology and Cosmetics?

The introduction of Skin+CELL illustrates how companies operating in dermatology are bridging gaps between clinical science and consumer products. By leveraging oncology expertise, Incanthera has positioned itself in a growing segment of dermatology-driven cosmetics. These products reflect wider trends within UK-listed companies, where innovation in delivery technology and formulation plays a crucial role. The focus on skin health, UV protection, and resilience illustrates the broader shift towards scientifically validated cosmetic products.